Neuroinflammation in Dementia-Therapeutic Directions in a COVID-19 Pandemic Setting.
Cells
; 11(19)2022 09 22.
Artigo
em Inglês
| MEDLINE | ID: covidwho-2109954
ABSTRACT
Although dementia is a heterogenous group of diseases, inflammation has been shown to play a central role in all of them and provides a common link in their pathology. This review aims to highlight the importance of immune response in the most common types of dementia. We describe molecular aspects of pro-inflammatory signaling and sources of inflammatory activation in the human organism, including a novel infectious agent, SARS-CoV-2. The role of glial cells in neuroinflammation, as well as potential therapeutic approaches, are then discussed. Peripheral immune response and increased cytokine production, including an early surge in TNF and IL-1ß concentrations activate glia, leading to aggravation of neuroinflammation and dysfunction of neurons during COVID-19. Lifestyle factors, such as diet, have a large impact on future cognitive outcomes and should be included as a crucial intervention in dementia prevention. While the use of NSAIDs is not recommended due to inconclusive results on their efficacy and risk of side effects, the studies focused on the use of TNF antagonists as the more specific target in neuroinflammation are still very limited. It is still unknown, to what degree neuroinflammation resulting from COVID-19 may affect neurodegenerative process and cognitive functioning in the long term with ongoing reports of chronic post-COVID complications.
Palavras-chave
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
MEDLINE
Assunto principal:
Demência
/
COVID-19
Tipo de estudo:
Estudo prognóstico
Tópicos:
Covid persistente
Limite:
Humanos
Idioma:
Inglês
Ano de publicação:
2022
Tipo de documento:
Artigo
País de afiliação:
Cells11192959
Similares
MEDLINE
...
LILACS
LIS